Long-term safety and efficacy of daclizumab beta in relapsing–remitting multiple sclerosis: 6-year results from the SELECTED open-label extension study

被引：0
作者：
Ralf Gold
Ernst-Wilhelm Radue
Gavin Giovannoni
Krzysztof Selmaj
Eva Kubala Havrdova
Xavier Montalban
Dusan Stefoski
Till Sprenger
Randy R. Robinson
Sami Fam
Jonathan Smith
Spyros Chalkias
Giorgio Giannattasio
Gabriel Lima
Wanda Castro-Borrero
机构：
[1] St. Josef-Hospital/Ruhr-University Bochum,Medical Image Analysis Center
[2] University Hospital Basel,Barts and The London School of Medicine and Dentistry
[3] Queen Mary University of London,Department of Neurology
[4] University of Warmia and Mazury,Department of Neurology, First Faculty of Medicine
[5] Charles University,undefined
[6] Hospital Vall d’Hebron University,undefined
[7] Rush University Medical Center,undefined
[8] DKD Helios Klinik Wiesbaden,undefined
[9] AbbVie Inc.,undefined
[10] Biogen,undefined
[11] Biogen,undefined
来源：
Journal of Neurology | 2020年 / 267卷
关键词：
Daclizumab beta; Relapsing–remitting multiple sclerosis; SELECTED; Clinical trial;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：2851 / 2864
页数：13
相关论文
共 50 条
  • [31] A multicenter, open-label, long-term study of three-year infliximab administration in Japanese patients with ankylosing spondylitis
    Kobayashi, Shigeto
    Yoshinari, Toru
    MODERN RHEUMATOLOGY, 2017, 27 (01) : 142 - 149
  • [32] Etanercept treatment for extended oligoarticular juvenile idiopathic arthritis, enthesitis-related arthritis, or psoriatic arthritis: 6-year efficacy and safety data from an open-label trial
    Ivan Foeldvari
    Tamàs Constantin
    Jelena Vojinović
    Gerd Horneff
    Vyacheslav Chasnyk
    Joke Dehoorne
    Violeta Panaviene
    Gordana Sušić
    Valda Stanevicha
    Katarzyna Kobusinska
    Zbigniew Zuber
    Bogna Dobrzyniecka
    Irina Nikishina
    Brigitte Bader-Meunier
    Luciana Breda
    Pavla Doležalová
    Chantal Job-Deslandre
    Ingrida Rumba-Rozenfelde
    Nico Wulffraat
    Ronald D. Pedersen
    Jack F. Bukowski
    Bonnie Vlahos
    Alberto Martini
    Nicolino Ruperto
    Arthritis Research & Therapy, 21
  • [33] Efficacy and safety of alogliptin added to metformin in Japanese patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial with an open-label, long-term extension study
    Seino, Y.
    Miyata, Y.
    Hiroi, S.
    Hirayama, M.
    Kaku, K.
    DIABETES OBESITY & METABOLISM, 2012, 14 (10) : 927 - 936
  • [34] Long-term Safety and Efficacy of Single-tablet Combinations of Solifenacin and Tamsulosin Oral Controlled Absorption System in Men with Storage and Voiding Lower Urinary Tract Symptoms: Results from the NEPTUNE Study and NEPTUNE II Open-label Extension
    Drake, Marcus J.
    Chapple, Christopher
    Sokol, Roman
    Oelke, Matthias
    Traudtner, Klaudia
    Klaver, Monique
    Drogendijk, Ted
    Van Kerrebroeck, Philip
    EUROPEAN UROLOGY, 2015, 67 (02) : 262 - 270
  • [35] Safety and efficacy of subcutaneous tocilizumab in systemic sclerosis: results from the open-label period of a phase II randomised controlled trial (faSScinate)
    Khanna, Dinesh
    Denton, Christopher P.
    Lin, Celia J. F.
    van Laar, Jacob M.
    Frech, Tracy M.
    Anderson, Marina E.
    Baron, Murray
    Chung, Lorinda
    Fierlbeck, Gerhard
    Lakshminarayanan, Santhanam
    Allanore, Yannick
    Pope, Janet E.
    Riemekasten, Gabriela
    Steen, Virginia
    Mueller-Ladner, Ulf
    Spotswood, Helen
    Burke, Laura
    Siegel, Jeffrey
    Jahreis, Angelika
    Furst, Daniel E.
    ANNALS OF THE RHEUMATIC DISEASES, 2018, 77 (02) : 212 - 220
  • [36] Etanercept treatment for extended oligoarticular juvenile idiopathic arthritis, enthesitis-related arthritis, or psoriatic arthritis: 6-year efficacy and safety data from an open-label trial
    Foeldvari, Ivan
    Constantin, Tamas
    Vojinovic, Jelena
    Horneff, Gerd
    Chasnyk, Vyacheslav
    Dehoorne, Joke
    Panaviene, Violeta
    Susic, Gordana
    Stanevicha, Valda
    Kobusinska, Katarzyna
    Zuber, Zbigniew
    Dobrzyniecka, Bogna
    Nikishina, Irina
    Bader-Meunier, Brigitte
    Breda, Luciana
    Dolezalova, Pavla
    Job-Deslandre, Chantal
    Rumba-Rozenfelde, Ingrida
    Wulffraat, Nico
    Pedersen, Ronald D.
    Bukowski, Jack F.
    Vlahos, Bonnie
    Martini, Alberto
    Ruperto, Nicolino
    ARTHRITIS RESEARCH & THERAPY, 2019, 21 (1)
  • [37] Long-term safety and efficacy of safinamide as add-on therapy in levodopa-treated Japanese patients with Parkinson's disease with wearing-off: Results of an open-label study
    Tsuboi, Yoshio
    Hattori, Nobutaka
    Yamamoto, Akihiko
    Sasagawa, Yuji
    Nomoto, Masahiro
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2020, 416
  • [38] Additional Safety and Exploratory Efficacy Data at 48 and 60 Months from Open-HART, an Open-Label Extension Study of Pridopidine in Huntington Disease
    McGarry, Andrew
    Auinger, Peggy
    Kieburtz, Karl
    Geva, Michal
    Mehra, Munish
    Abler, Victor
    Grachev, Igor D.
    Gordon, Mark Forrest
    Savola, Juha-Matti
    Gandhi, Sanjay
    Papapetropoulos, Spyridon
    Hayden, Michael
    JOURNAL OF HUNTINGTONS DISEASE, 2020, 9 (02) : 173 - 184
  • [39] Long-term safety of nebivolol and valsartan combination therapy in patients with hypertension: an open-label, single-arm, multicenter study
    Neutel, Joel M.
    Giles, Thomas D.
    Punzi, Henry
    Weiss, Robert J.
    Li, Huiling
    Finck, Amy
    JOURNAL OF THE AMERICAN SOCIETY OF HYPERTENSION, 2014, 8 (12) : 915 - 920
  • [40] Safety and Efficacy of Tetrabenazine and Use of Concomitant Medications During Long-Term, Open-Label Treatment of Chorea Associated with Huntington's and Other Diseases
    Shen, Vivienne
    Clarence-Smith, Kathleen
    Hunter, Christine
    Jankovic, Joseph
    TREMOR AND OTHER HYPERKINETIC MOVEMENTS, 2013, 3
12345